Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2003
10/23/2003US20030199485 Novel anti-inflammatory androstane derivative
10/23/2003US20030199479 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/23/2003US20030199478 For modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation
10/23/2003US20030199476 Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof
10/23/2003US20030199474 Administering compounds such as (3,4-dihydroxy-5-(2-hydroxyethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione for inhibiting the invasion and/or metastasis of a carcinoma in a mammal
10/23/2003US20030199464 Regeneration of endogenous myocardial tissue by induction of neovascularization
10/23/2003US20030199456 Sodium channel blockers
10/23/2003US20030199441 Procollagen (III) Propeptides and Related Substances for Treating Fibrotic Diseases
10/23/2003US20030199103 Novel amino acid sequences for human epidermal growth factor-like polypeptides
10/23/2003US20030199070 Crystallization of ribosome recycling factor (RRF) and method of developing inhibitor of RRF
10/23/2003US20030199067 Growth arrest homeobox gene
10/23/2003US20030199043 Therapeutic proteins (including polypeptide, antibody, peptide or fragment or variants)fused to albumin or fragment or variant linked by a linker peptide; nonglycosylated
10/23/2003US20030199042 Novel morphogenic protein
10/23/2003US20030199040 First fusion polypeptide is linked to a second fusion polypeptide via disulfide bond between the heavy chain and light chain polypeptide, where in the first polypeptide binds interleukin-18
10/23/2003US20030199002 For the treatment, management, or prevention of disorders associated with abnormal expression and/ or activity of clk-2 (clock-2) nucleic acids; treating or preventing disorders associated with decreased/increased apoptosis e.g. cancer
10/23/2003US20030198986 Differential screening of a rat hippocampus cDNA library; a cDNA species encoding a novel protein designated Hct-1 is shown to be related to cytochromes P450
10/23/2003US20030198954 For forensic analyses, chromosome tissue/cell/organelle-specific markers, production of expression vectors, screening and diagnosis assays
10/23/2003US20030198953 For diagnosis, treatment, and prevention of related disorders
10/23/2003US20030198949 Viral polypeptides that regulate or modulate apoptosis
10/23/2003US20030198939 In vitro culturing of monocytes in presence of monoclonal antibody
10/23/2003US20030198691 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
10/23/2003US20030198674 Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
10/23/2003US20030198666 Side effect reduction; using mixture of insulin and adjuvant
10/23/2003US20030198643 Adjuvant enhanced immunotherapy
10/23/2003US20030198635 Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
10/23/2003US20030198620 Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
10/23/2003US20030198602 Improved absorption; drug delivery
10/23/2003EP1494675A2 Inhibitors of akt activity
10/23/2003CA2485679A1 Compounds and methods for inducing apoptosis in proliferating cells
10/23/2003CA2484261A1 Piperidine derivatives having ccr3 antagonism
10/23/2003CA2482937A1 A novel crystal of anhydride of a quinoxalinedione derivative
10/23/2003CA2482904A1 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
10/23/2003CA2482903A1 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
10/23/2003CA2482718A1 Derivatives of the il-2 receptor gamma chain, their production and use
10/23/2003CA2482634A1 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction
10/23/2003CA2482544A1 2-(2,6-dichlorophenyl)-diarylimidazoles
10/23/2003CA2482387A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use
10/23/2003CA2482313A1 Heterocyclic compounds
10/23/2003CA2482312A1 Thienyl compounds
10/23/2003CA2481855A1 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
10/23/2003CA2481752A1 Composition for modulating a physiological reaction or inducing an immune response
10/23/2003CA2481747A1 Recombinant anti-interleukin-9 antibodies
10/23/2003CA2481683A1 Ansamycin formulations and methods for producing and using same
10/23/2003CA2481669A1 Preparation and use of a stable formulation of allosteric effector compounds
10/23/2003CA2481532A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2481509A1 Her-2 receptor tyrosine kinase molecules and uses thereof
10/23/2003CA2481478A1 Stimulation of nerve cell regeneration
10/23/2003CA2481391A1 Preventives/remedies for hotflash
10/23/2003CA2481387A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003CA2481385A1 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
10/23/2003CA2481344A1 Inhibitors of glycinamide ribonucleotide transformylase
10/23/2003CA2481320A1 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
10/23/2003CA2481313A1 Bicyclic amides
10/23/2003CA2481272A1 The use of devazepide as analgesic agent
10/23/2003CA2481207A1 Methods of treatment using ctla-4 antibodies
10/23/2003CA2481178A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
10/23/2003CA2481074A1 Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
10/23/2003CA2480879A1 Tyrosine kinase inhibitors
10/23/2003CA2480860A1 Tri-substituted heteroaryls and methods of making and using the same
10/23/2003CA2480858A1 Treatment of gastroparesis
10/23/2003CA2480856A1 Substituted aryl amides
10/23/2003CA2480814A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation
10/23/2003CA2480759A1 Improved prodrugs of cc-1065 analogs
10/23/2003CA2480758A1 Tyrosine kinase inhibitors
10/23/2003CA2480754A1 Tyrosine kinase inhibitors
10/23/2003CA2480745A1 Methods for treating tweak-related conditions
10/23/2003CA2480415A1 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
10/23/2003CA2480410A1 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
10/23/2003CA2480079A1 Antiangiogenic active immunotherapy
10/23/2003CA2479996A1 Compositions for delivering enyzmes involved in acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolicdisorders using such raav virons
10/23/2003CA2479835A1 An ephrin-b receptor protein involved in carcinoma
10/23/2003CA2479714A1 Branched polyamine steroid derivatives
10/23/2003CA2478392A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003CA2477692A1 Cyanamides useful as reversible inhibitors of cysteine proteases
10/23/2003CA2470016A1 Antibiotic product, use and formulation thereof
10/23/2003CA2466301A1 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
10/22/2003EP1355159A1 Use of fragments of carbamyl phosphate synthetase I (CPS 1) for the diagnosis of inflammatory diseases and sepsis
10/22/2003EP1355152A1 Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen
10/22/2003EP1354947A1 Novel polypeptide
10/22/2003EP1354891A1 Medicament comprising NK4 gene or recombinant NK4 protein
10/22/2003EP1354888A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines
10/22/2003EP1354884A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
10/22/2003EP1354882A1 Dipeptidyl peptidase iv inhibitor
10/22/2003EP1354880A1 Halogen compounds having thrombopoietin receptor agonism
10/22/2003EP1354878A2 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
10/22/2003EP1354873A1 Salt of perindopril and pharmaceutical compositions containing it
10/22/2003EP1354871A1 Biphenyl derivatives
10/22/2003EP1354868A1 Perfluoronated cycle-containing tertiary amines used as a basis for gas-conveying emulsions and device for the production thereof
10/22/2003EP1354603A1 Concomitant drugs
10/22/2003EP1354602A1 Medicinal compositions containing diuretic and insulin resistance-improving agent
10/22/2003EP1354601A1 Transplantation rejection inhibitors
10/22/2003EP1354598A2 Therapeutic uses of BR43X2 soluble receptors
10/22/2003EP1354597A2 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
10/22/2003EP1354590A1 Drugs against articular failure
10/22/2003EP1354585A1 Use of molindone or derivatives thereof for the manufacture of a medicament in the treatment of oppositional defiant disorders and conduct disorders
10/22/2003EP1354047A2 Methods for screening compounds that modulate lipid metabolism
10/22/2003EP1354033A2 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
10/22/2003EP1354032A2 Gene regulation therapy involving ferritin
10/22/2003EP1353954A2 Anticoagulants and their uses
10/22/2003EP1353952A2 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
1 ... 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 ... 1564